BioSpace News Archive

The U.S. Food and Drug Administration approved Genentech’s Enspryng (satralizumab-mwge) as a subcutaneous treatment for adults with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder.

The 11-person team at Codagenix may be tiny, but it has big plans for the company’s new COVID-19 vaccine.

Under terms of the deal, Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which represents an aggregate equity value of approximately $3.68 billion.

UNITY Biotechnology reported that the 12-week results from its Phase II study of UBX0101 in moderate-to-severe painful osteoarthritis (OA) of the knee failed to show improvement over placebo.

In the midst of an international pandemic, three high-profile public health officials are leaving government service.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 19, 2020.

“Today’s announcement puts another building block in place as the Nation moves toward a safe and effective COVID-19 vaccine,” stated Robert Redfield, director of the U.S. Centers for Disease Control and Prevention.

Bristol Myers Squibb plunked down $475 million for the exclusive license to Dragonfly Therapeutics’ interleukin-12 (IL-12) investigational immunotherapy program.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 17, 2020.

Lumenis Ltd. , the world’s largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, is proud to announce its latest innovation, the NuEra Tight with FocalRF technology . The platform introduces a breakthrough in personalized non-invasive RF body treatments to match the unique needs of eve